Simulations Plus, Inc. (NASDAQ:SLP) – Research analysts at Taglich Brothers decreased their Q1 2019 EPS estimates for Simulations Plus in a research note issued on Tuesday, December 4th. Taglich Brothers analyst H. Halpern now anticipates that the technology company will post earnings per share of $0.11 for the quarter, down from their previous estimate of $0.12. Taglich Brothers also issued estimates for Simulations Plus’ Q2 2019 earnings at $0.12 EPS, Q3 2019 earnings at $0.15 EPS, FY2019 earnings at $0.46 EPS, Q1 2020 earnings at $0.12 EPS, Q2 2020 earnings at $0.15 EPS, Q3 2020 earnings at $0.19 EPS, Q4 2020 earnings at $0.09 EPS and FY2020 earnings at $0.55 EPS.
A number of other research firms have also recently issued reports on SLP. BidaskClub upgraded Simulations Plus from a “buy” rating to a “strong-buy” rating in a report on Wednesday, August 15th. Zacks Investment Research cut Simulations Plus from a “buy” rating to a “hold” rating in a report on Wednesday, September 19th.
SLP opened at $19.43 on Wednesday. Simulations Plus has a 52-week low of $14.25 and a 52-week high of $23.95. The firm has a market cap of $328.55 million, a P/E ratio of 38.36 and a beta of -0.71.
Simulations Plus (NASDAQ:SLP) last posted its quarterly earnings data on Wednesday, November 14th. The technology company reported $0.07 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.06 by $0.01. Simulations Plus had a return on equity of 24.97% and a net margin of 30.11%. The company had revenue of $6.70 million during the quarter, compared to analysts’ expectations of $5.98 million.
The company also recently announced a quarterly dividend, which was paid on Thursday, November 8th. Shareholders of record on Thursday, November 1st were issued a $0.06 dividend. This represents a $0.24 annualized dividend and a dividend yield of 1.24%. The ex-dividend date of this dividend was Wednesday, October 31st. Simulations Plus’s dividend payout ratio is 48.00%.
In other Simulations Plus news, Director Walter S. Woltosz sold 18,500 shares of the company’s stock in a transaction on Thursday, September 27th. The stock was sold at an average price of $19.92, for a total value of $368,520.00. Following the completion of the sale, the director now directly owns 5,417,908 shares in the company, valued at approximately $107,924,727.36. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 33.45% of the stock is currently owned by corporate insiders.
Hedge funds have recently modified their holdings of the business. MetLife Investment Advisors LLC purchased a new stake in shares of Simulations Plus in the 2nd quarter worth $129,000. Bank of Montreal Can purchased a new stake in shares of Simulations Plus in the 2nd quarter worth $186,000. ClariVest Asset Management LLC purchased a new stake in shares of Simulations Plus in the 3rd quarter worth $210,000. Acadian Asset Management LLC purchased a new stake in shares of Simulations Plus in the 2nd quarter worth $233,000. Finally, Citadel Advisors LLC purchased a new stake in shares of Simulations Plus in the 2nd quarter worth $246,000. Institutional investors and hedge funds own 38.87% of the company’s stock.
Simulations Plus Company Profile
Simulations Plus, Inc develops drug discovery and development software for mechanistic modeling and simulation worldwide. The company offers GastroPlus, which simulates the absorption, pharmacokinetics (PK), and pharmacodynamics of drugs administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments, which measure the rate of dissolution of the drug and additives in a dosage form; and MembranePlus, which simulates laboratory experiments.
Featured Article: Depreciation
Receive News & Ratings for Simulations Plus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Simulations Plus and related companies with MarketBeat.com's FREE daily email newsletter.